BCAT
BlackRock Capital Allocation Trust
There isn't enough reported data to score BCAT yet.
CIFR
Cipher Mining Inc.
There isn't enough reported data to score CIFR yet.
BCAT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| N/A | |
| N/A |
There isn't enough reported data to rate BCAT's fundamentals.
CIFR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
CIFR's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like CIFR.
BCAT PE Valuation
BCAT has no meaningful PE right now: it lost money over the past year.
CIFR PE Valuation
CIFR has no meaningful PE right now: it lost money over the past year.
BCAT Forward outlook
There aren't enough analyst estimates for BCAT to show an outlook.
CIFR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CIFR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BCAT Earnings Per Share
BCAT and CIFR do not have enough comparable growth data to identify a winner.
CIFR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.06 | -$2.86 |
| Q2 2026 | -$2.85 | -$2.40 |
| Q1 2026 | -$2.32 | -$1.94 |
| Q4 2025 | -$2.15 | -$2.01 |
| Q3 2025 | -$0.20 | -$0.07 |
| Q2 2025 | -$0.45 | -850% |
| Q1 2025 | -$0.38 | -733% |
| Q4 2024 | -$0.14 | -$0.04 |
CIFR lost $3.06 per share over the past year, and its loss has widened in each of the last four quarters.
BCAT Quarterly Revenue
BCAT and CIFR do not have enough comparable growth data to identify a winner.
CIFR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $26.7M | -63% |
| Q2 2026 | $24.8M | -43% |
| Q1 2026 | $34.8M | -29% |
| Q4 2025 | $59.7M | +41% |
| Q3 2025 | $71.7M | +198% |
| Q2 2025 | $43.6M | +18% |
| Q1 2025 | $49M | +1.7% |
| Q4 2024 | $42.2M | -2.8% |
CIFR's revenue has slid since its 2025 peak: $27M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -269% | -217 points |
| Q2 2026 | -316% | -212 points |
| Q1 2026 | -329% | -251 points |
| Q4 2025 | -503% | -544 points |
| Q3 2025 | -52% | +327 points |
| Q2 2025 | -104% | -60 points |
| Q1 2025 | -78% | -175 points |
| Q4 2024 | 40% | +4 points |
CIFR's operating margin was โ269% last quarter, down 217 points from the same quarter a year ago.
BCAT Free Cash Flow
BCAT and CIFR do not have enough comparable growth data to identify a winner.
CIFR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7B | -$1.4B |
| Q2 2026 | -$653.8M | -$566.3M |
| Q1 2026 | -$462.5M | -$390.7M |
| Q4 2025 | -$280.3M | -$204.2M |
| Q3 2025 | -$256.2M | -$173.1M |
| Q2 2025 | -$87.5M | -$54.3M |
| Q1 2025 | -$71.8M | -$37.3M |
| Q4 2024 | -$76.1M | +$38M |
CIFR's free cash flow was โ$3.1B over the past year, against โ$492M the year before. Free cash flow isn't a meaningful measure for financial services companies like CIFR.
BCAT Net Leverage
CIFR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.3x | Net Cash |
| Q1 2025 | 125.4x | High |
| Q4 2024 | 0.5x | Very low |
| Q3 2024 | -0.7x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q2 2023 | -0.1x | Net Cash |
CIFR has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CIFR.
BCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.3 | Neutral |
| Stochastic | 18.0 | Oversold |
BCAT's weekly RSI is 34 (neutral) and its Stochastic is 18 (oversold).
CIFR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 7.8 | Oversold |
CIFR's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
BCAT PE vs Financial Services Sector
BCAT has no meaningful PE right now: it lost money over the past year.
CIFR PE vs Financial Services Sector
| Metric | CIFR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | โ |
CIFR has no meaningful PE right now: it lost money over the past year.
BCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.5 | 2.1% below |
| 20 week MA | $14.8 | 11% below |
| 50 week MA | $14.9 | 11% below |
| 100 week MA | $14.9 | 11% below |
| 200 week MA | $15.2 | 13% below |
BCAT is in a downtrend: it's below all five of its weekly moving averages, and 13% below its 200-week average.
CIFR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 33% below |
| 20 week MA | $15.5 | 54% below |
| 50 week MA | $17.0 | 58% below |
| 100 week MA | $12.2 | 41% below |
| 200 week MA | $7.86 | 9% below |
CIFR is in a downtrend: it's below all five of its weekly moving averages, and 9% below its 200-week average.
BCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.0 | $23.3 | +17% |
| 2021 | $23.3 | $18.8 | -19% |
| 2022 | $18.8 | $13.9 | -26% |
| 2023 | $13.9 | $15.0 | +7.9% |
| 2024 | $15.0 | $15.3 | +2.6% |
| 2025 | $15.3 | $14.2 | -7.2% |
| 2026 YTD | $14.2 | $13.2 | -7.3% |
BCAT has the edge over CIFR on returns for 2026, with the stronger performance.
CIFR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $9.95 | +0.3% |
| 2021 | $9.95 | $5.21 | -48% |
| 2022 | $5.21 | $0.54 | -90% |
| 2023 | $0.54 | $4.13 | +665% |
| 2024 | $4.13 | $4.86 | +18% |
| 2025 | $4.86 | $15.2 | +213% |
| 2026 YTD | $15.2 | $7.15 | -53% |
CIFR's yearly returns have swung widely, from +665% in 2023 to โ90% in 2022. It's down 53% so far in 2026.